Protocol Ledger

NCT06866405 · Phase III · RECRUITING

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

Interventional Phase III clinical trial protocol NCT06866405 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-16 Enrollment: 550 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06866405
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)550 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06866405
Protocol FieldVerified Registry Value
NCT IdentifierNCT06866405
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment550 participants (ESTIMATED)
Registered Start Date2025-04-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI